NCT02431559 2022-10-10Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerLudwig Institute for Cancer ResearchPhase 1/2 Completed53 enrolled 22 charts
NCT01836029 2019-10-29Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCelgenePhase 2 Completed195 enrolled 13 charts